BIOTECHNOLOGY AND UNCERTAINTY
The global biotechnology revolution purportedly began during the late 1970s, when the biological "heuristic" in health care technology was expected to both rival and ultimately prove superior to existing chemistry-based approaches to health and health care. Rooted in new discoveries in genetics and the promise of genetic engineering, and fuelled by a flurry of government research support, venture capital and increasingly entrepreneurial universities, biotechnology was expected to revolutionize how human therapeutics were developed, screened, and delivered. Biotechnological tools were expected to rationalize drug development. They would lead to new diagnostic tools.
Recombinant DNA techniques would allow scientists to re-engineer cells to produce new and "smarter" proteins, the basis for a new generation of therapeutics. The introduction of biotech would in effect re-structure global human health care industry, as pharmaceutical firms increasingly turned to smaller, specialized and more cutting-edge biotech firms for new screening techniques and drug candidates. Biotechnology was imagined as an enabling technology, a platform technology and a source of knowledge for advancing human health care. Simply put, the possibilities for applying biotechnology to health and health care seemed endless.
As with all revolutionary moments, however, the growth of biotechnology and the future development of a global biotech industry were inherently uncertain. As a sciencebased industry, it was unclear whether the science of biotechnology would actually result in more efficient and more effective health care interventions: will it work? Venture capital's enthusiasm notwithstanding, there was tremendous uncertainty surrounding biotech's economic viability as well, especially seeing as new discoveries at the time were still considerably far-from-market: will it have value (Pisano, 2006 )? Between 1998 and 2003 billion US was invested by the private sector in the US. Nearly $30 billion the US government is expended each year for upstream life sciences research (Casper, 2007 ). Yet, despite such large-scale investments, the global (and US) biotechnology sector, as an industry, has fallen far short of initial, albeit uncertain, expectations. Recent data from the 2000s, for instance, show that biotechnological techniques have not in fact resulted in more effective drug development processes. Biopharmaceuticals have not revolutionized the field of human therapeutics nor have they radically altered the business model of the conventional pharmaceutical industry. And economically, the global biotechnology industry has not fared particularly well (Hopkins et al. 2007 ). While there have been some -a small few -major success cases, the industry as a whole has lost billions of dollars ($40 billion according to a 2004
Wall Street Journal report). Two firms, US-based Amgen and Genentech, account for nearly 50% of all positive cash flow in the biotech sector. As of 2003, there were nearly 1500 biotechnology firms in the US alone, though less than 200 biotech products had actually made it to market (Pfeffer, 2004: 104) .
It was against this uncertain backdrop that Hong Kong entered into the biotechnology sector during the early 1990s. Driven by the government's new industrial upgrading initiatives, and by leveraging Hong Kong's entrepreneurial spirit and transparent corporate regulatory environment, Hong Kong looked to make significant inroads into life sciences industry (Berger and Lester, 1997) . Government commitment was high, by Hong Kong standards. Public funding for biotechnology R&D, allocated through the government's industry support fund (ISF), increased from just 7% in 1994/1995 of the fund's total investment to over 40% in 1997 /1998 (Tsang and Lo, 1998 Hong Kong, government resources account for a relatively large portion of R&D expenditures. Industry makes up approximately 30% of the total R&D spending (Baark, 2005: 8) , whereas in most other advanced economies firms account for between twothirds and three-quarters of the national R&D bill. In the field of biotech specifically, the 4 number of firms in Hong Kong is quite small. The government suggests that there are between 250 to 300 "biotechnology-related companies," though this figure represents a rather expansive definition of biotechnology.
1 Industry insiders estimate that Hong Kong is actually home to less than 50 "true" biotech firms. Indeed, because of reasons related to scale, or lack thereof in Hong Kong, biotechnology's and bio-industry's uncertainties are intensely magnified. With a population of just 7 million people, Hong Kong's efforts to become a cutting-edge technology innovator are continually frustrated due to a relatively small talent pool, fewer resources in general, and the absence of a critical mass of firms in the life sciences sector. This paper illuminates ways in which Hong Kong may begin to overcome some of these challenges.
BIOTECHNOLOGY IN HONG KONG
Despite such uncertainty -after all, technological and economic uncertainty surrounding the biotechnology sector is a global concern -Hong Kong has made significant strides in building up its R&D capacity in the life sciences. In the biotechnology field specifically, almost all R&D funding comes from government coffers.
As I indicated above, the ISF allocated over 40% of its funds to biotechnology projects during the mid to late 1990s. Prior to 1998, the applied research fund (ARF), the government's investment fund earmarked for industry, allocated $16.6 million HK of its total $97.3 million HK, or 17%, into biotechnology firms, of which one, Hong Kong Transgenic Ltd., was in fact an equity investment rather than a loan. technology, which meant that while it remained a government priority, funding for biotech was to be on an "exceptional basis" (Wan, 2005: 919 Pearl River Delta (PRD) region is the basis of Hong Kong's economic future and its ambitions for industrial upgrading. With respect to the life sciences sector specifically, the HK SAR "is poised to play a significant role in the development of biotechnology industry in China" (Chang, 1999) . During the early 2000s, about two-thirds of Hong Kong's pharmaceutical and health care related exports went to China (Nature, 2001: 5).
Moreover, Hong Kong, given its global reputation as a services and logistics hub in Asia, is positioned to play a "supporting role" for biotech development in the mainland (Frost and Sullivan, 2002) . Its advanced health care infrastructure and world-class universities make Hong Kong an ideal place to "bridge" global life sciences industries with China (Wong, 2006: 221-2 R&D projects to local universities to gather data on the efficacy and safety of its products.
Eu Yan Sang Chinese Medicines invested $10 million HK in 2000 to seed a collaborative project with the CUHK, specifically a pharmacological study of the firm's "meno-ease" product. The initiative was co-funded by the government's ITF. For the CUHK, the research collaboration with Eu Yan Sang was about demonstrating "proof" of efficacy of traditional herbal formulas for mitigating the effects of menopause. From the perspective of the firm, the "modernizing" effort was intended to demonstrate for the market the product's efficacy and safety in inducing the body to naturally develop estrogen (rather than require the ingestion of the hormone). regularly, for the treatment of common ailments and illnesses (Lau, 2000) . However, the limited size of the local market in Hong Kong and the large number of local firms mean that the future growth of Hong Kong's TCM sector requires expansion into the Chinese market. And the fact that until recently TCM regulations were relatively lax, excessive market crowding among local firms, especially small manufacturers without GMP certification, is very pronounced. Small firms may not survive in the long run while large firms are constrained in the ability to expand their operations into the Chinese market.
PuraPharm is one Hong Kong TCM firm which has gained sizable market share in China. Using proprietary technologies to derive novel molecular formulations from traditional herb mixtures, PuraPharm has built a core business around the production of TCM "granules," or the de facto isolation and manufacture of key medicinal ingredients.
In order to gain closer access to raw materials (herbs), PuraPharm established early on manufacturing facilities in Guanxi province, China. The key point is that while during the mid 1990s, the future of Hong Kong's life sciences industry centered on its ability to move up the manufacturing value chain, and specifically in the TCM sector, more recent developments during the 2000s laid the foundation for considerably more lofty ambitions over the longer term, which is to turn Hong Kong into a biotech innovator.
DISCOVERED IN HONG KONG?
Efforts to increase R&D collaboration among Hong Kong researchers and others translating discoveries from the university lab bench into a commercially viable product or service is an extremely high risk endeavor. In this respect, it is still too early to determine whether Hong Kong will be able to become a biotech innovator. Still, it is clear that there exists several "gaps" which need to be addressed at the outset (Branscomb and Auerswald, 2001 ). These will be addressed in turn below.
Midstream Capacity
Technological innovation requires the translation of upstream research into a commercial product or service. In the field of biotechnology, there are literally thousands of potential "leads," though the reality is that most will either languish or fail to make it to the market. There is no institutional equivalent of the ITRI in Hong Kong's biotech sector.
Publicly funded research institutions dedicated to fill the midstream "gap" in the life sciences do not exist. When asked, most repeat the mantra that the Hong Kong government, unlike the state in much of the rest of northeast Asia, does not "pick winners." Reducing risk and uncertainty to incentivize otherwise risk averse firms to enter into the biotechnology sector is considered excessive government intervention. 
Investment
The valley of death -the "challenges faced by would-be innovators seeking to make the transition from scientific breakthrough to market-ready prototype" -is a attendees and 28 partnering initiatives; the significance, of course, is that the inaugural event took place just this past year. Rather, medium term achievements measured in terms of intellectual property generation, the inflow of foreign direct investment, the formation of transnational R&D partnerships, the completion of a phase 2 clinical trial, and so on, need to be understood as indicators of progress.
LOOKING FORWARD

